cookies on this device, please see our
cookie management page. If you close this message or continue to use this site, you consent
Dechra Pharmaceuticals (DPH) spent most of the first half integrating its €135m (£110m) Eurovet acquisition. That should ultimately mean cost savings totalling £4m through the rationalisation of different manufacturing sites. However, Dechra's performance will be weighted to the second half of the year, as it deals with a variety of operational issues in its main business divisions that have arisen from its acquisition strategy.